---
title: "ADA 2025: Semaglutide taken orally shown to reduce cardiovascular risk in type 2 diabetes patients"
date: "2025-06-23T09:29:32.000Z"
publishedDate: "23 juin 2025"
summary: "Research presented at the American Diabetes Association (ADA) 2025 scientific session (20–23 June, Chicago, USA) has shown that oral semaglutide offers a cardiovascular benefit for individuals with type 2 diabetes, by lowering their risk for major adverse cardiovascular events (MACE). Semaglutide is typically administered via an injection, but it is thought that delivering the anti-diabetes [&#8230;] The post ADA 2025: Semaglutide taken orally shown to reduce cardiovascular risk in type 2 diabetes patients appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/ada-2025-semaglutide-taken-orally-shown-to-reduce-cardiovascular-risk-in-type-2-diabetes-patients/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-06-23-ada-2025-semaglutide-taken-orally-shown-to-reduce-cardiovascular-risk-in-type-2-diabetes-patients"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2017/07/white-pills.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/ada-2025-semaglutide-taken-orally-shown-to-reduce-cardiovascular-risk-in-type-2-diabetes-patients/"
---

![ADA 2025: Semaglutide taken orally shown to reduce cardiovascular risk in type 2 diabetes patients](https://cardiovascularnews.com/wp-content/uploads/sites/14/2017/07/white-pills.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/ada-2025-semaglutide-taken-orally-shown-to-reduce-cardiovascular-risk-in-type-2-diabetes-patients/*

## L’essentiel

Research presented at the American Diabetes Association (ADA) 2025 scientific session (20–23 June, Chicago, USA) has shown that oral semaglutide offers a cardiovascular benefit for individuals with type 2 diabetes, by lowering their risk for major adverse cardiovascular events (MACE). Semaglutide is typically administered via an injection, but it is thought that delivering the anti-diabetes [&#8230;] The post ADA 2025: Semaglutide taken orally shown to reduce cardiovascular risk in type 2 diabetes patients appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/ada-2025-semaglutide-taken-orally-shown-to-reduce-cardiovascular-risk-in-type-2-diabetes-patients/
